Capricor Therapeutics (FRA:4LN2) FCF Margin % : -101.94% (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Capricor Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Capricor Therapeutics's Free Cash Flow for the three months ended in Dec. 2023 was €-11.30 Mil. Capricor Therapeutics's Revenue for the three months ended in Dec. 2023 was €11.09 Mil. Therefore, Capricor Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was -101.94%.

As of today, Capricor Therapeutics's current FCF Yield % is -16.45%.

The historical rank and industry rank for Capricor Therapeutics's FCF Margin % or its related term are showing as below:

FRA:4LN2' s FCF Margin % Range Over the Past 10 Years
Min: -7348.98 Med: -497.09 Max: 61.03
Current: -109.65

During the past 13 years, the highest FCF Margin % of Capricor Therapeutics was 61.03%. The lowest was -7348.98%. And the median was -497.09%.

FRA:4LN2's FCF Margin % is ranked better than
53.82% of 1046 companies
in the Biotechnology industry
Industry Median: -145.305 vs FRA:4LN2: -109.65

Capricor Therapeutics FCF Margin % Historical Data

The historical data trend for Capricor Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Capricor Therapeutics FCF Margin % Chart

Capricor Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-678.45

-3,417.65

-7,342.86

61.05

-109.80

Capricor Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-846.58	125.77	-246.42	-152.40	-101.94

Competitive Comparison of Capricor Therapeutics's FCF Margin %

For the Biotechnology subindustry, Capricor Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Capricor Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Capricor Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Capricor Therapeutics's FCF Margin % falls into.

Capricor Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Capricor Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-25.35	/	23.088
	=	-109.80 %

Capricor Therapeutics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-11.3	/	11.085
	=	-101.94 %

Capricor Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Capricor Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Capricor Therapeutics (FRA:4LN2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Capricor Therapeutics Inc (FRA:4LN2) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

CAPR:USA

Address

10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121

Website

https://www.capricor.com

Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.

Capricor Therapeutics (FRA:4LN2) Headlines

No Headlines